Analyst upgrades:

• Deutsche Bank upgraded BT Group (NYSE: BT) to Buy from Hold as it believes the company's Q4 results could remove uncertainty and cost cutting initiatives could drive upside.
  
• Baird upgraded Stanley Works (NYSE: SWK) to Outperform from Neutral and raised their target to $42 from $34 citing valuation, solid execution, and growth potential.
  
• Citigroup upgraded Netflix (NASDAQ: NFLX) to Buy from Hold as it believes the recent sell-off presents an attractive buying opportunity. The firm believes Netflix has one of the best earnings outlooks in the internet sector and increased its target price to $52 from $37.
• AstraZeneca (NASDAQ: AZN) was upgraded to Buy from Neutral at UBS.
  
• Joy Global (NYSE: JOYG) and Bucyrus (NYSE: BUCY) were raised to Buy from Neutral at Goldman.

Analyst upgrades:

• Banc of America/Merrill upgraded Lincoln National (NYSE: LNC) to Buy from Underperform and raised its target to $17 from $10 citing expectations that the company will "qualify for and accept TARP funding."
  
• Credit Suisse upgraded AU Optronics (NYSE: AUO) to Outperform from Neutral as it believes inventory levels are low end demand is better than expected.
  
• JP Morgan upgraded Shaw Group (NYSE: SGR) to Overweight from Neutral. The firm views the recent pullback in shares as a buying opportunity given the company's attractive nuke position and expected ramp in government spending.
• Patterson-UTI Energy (NASDAQ: PTEN) was upgraded to Buy from Neutral at Goldman.
  
• Barrick Gold (NYSE: ABX) was raised to Overweight from Market Weight at Thomas Weisel.
  
• Stryker (NYSE: SYK) was lifted to Sector Perform from Underperform at RBC Capital.

Kendle International (NASDAQ: KNDL) provides a range of clinical development services to the biopharmaceutical industry. Offerings include clinical trial management, clinical data management, statistical analysis, medical writing, regulatory consulting and publication services. The company has expertise in a range of therapeutic areas, including oncology, cardiovascular disease, inflammation and central nervous system disorders. Kendle's Early Stage segment focuses on Phase I operations. The Late Stage unit handles Phase II through IV clinical trials, regulatory affairs, and biometrics offerings. Covance (NYSE: CVD) and Parexel International (NASDAQ: PRXL) are major competitors.

The firm surprised the Street earlier in the month, when it reported Q2 EPS of 52 cents and revenues of $127 million. Analysts had been looking for 46 cents and $115.3 million. The EPS figure was a company record. Management also guided FY08 EPS to $2.00-$2.15 ($1.90 consensus) and FY08 revenues to $490-$500 million ($468.76M consensus). Ladenburg Thalmann subsequently reiterated its "buy" recommendation and boosted its price target to $51.

MOST NOTEWORTHY: Fortress, ITT Educational Service and Kendle International were today's noteworthy initiations:

• Fortress Investment Group (NYSE: FIG) was initiated with a Hold rating and $18.50 target at Jefferies. The firm expects near-term volatility given the increasingly difficult private equity market.
  
• Banc of America assumed coverage of ITT Educational Service (NYSE: ESI) with a Buy rating and $130 target and believes the recent weakness creates an attractive entry point as they see continued margin expansion and upside to Street estimates.
  
• Susquehanna expects Kendle International (NASDAQ: KNDL) to benefit from positive trends in the Clinical Research Organization industry, expanded customer base and geographical reach, integration of Charles Rivers Laboratories (NYSE: CRL), and backlog. The firm started shares with a Positive rating.

OTHER INITIATIONS:

• China Security & Surveillance (NYSE: CSR) was initiated with an Overweight rating and $30 target at Lehman.
  
• Morgan Stanley started Akamai Technologies (NASDAQ: AKAM) with an Equal Weight rating and $39 target.
  
• Goldman resumed coverage of AU Optronics (NYSE: AUO) and Clorox (NYSE: CLX) with Neutral ratings.

MOST NOTEWORTHY: Catalyst Pharm, Ruth's Chris Steak House and Dynegy were today's noteworthy initiations:

• Rodman & Renshaw is optimistic on Catalyst Pharmaceutical Partners' (NASDAQ: CPRX) Vigabatrin in drug addiction, initiating shares with a Market Outperform rating and $9 target.
• SunTrust started Ruth's Chris Steak House (NASDAQ: RUTH) with a Neutral rating and $13 target, citing the difficult spending environment and cautious sentiment.
• Jefferies initiated shares of Dynegy Inc. (NYSE: DYN) with a Buy rating and $9 target and expects improved cash flow and earnings from the projected improvement in market heat rates in the Midwest and PJM.

OTHER INITIATIONS:

• Bear Stearns resumed coverage of Siemens AG (NYSE: SI) with an Outperform rating.
• Wachovia initiated the pharmaceutical services sector with an Overweight rating and started Covance Inc. (NYSE: CVD), Icon plc (NASDAQ: ICLR) and Kendle International (NASDAQ: KNDL) with Outperform ratings.